Catalyst
Slingshot members are tracking this event:
CytRx (CYTR) Reports Updated Results from Pivotal Phase 3 Trial of Aldoxorubicin in Patients with Second-Line Soft Tissue Sarcomas
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
CYTR |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 29, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Trial, Aldoxorubicin, Second-line Soft Tissue Sarcomas, Leiomyosarcoma, Liposarcoma